Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for Prophylaxis of Neutropenia in Pediatric Hematological Malignancies
NCT04497701Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Randomised, open-label trial of pegfilgrastim in lymphoma and leukemia (2 arms), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Incidence of febrile neutropenia (FN). Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
lymphomaleukemia
Beyond the preview
Go deeper on NCT04497701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497701.